BioNTech posted declining revenue and a net loss in Q4 2025 due to reduced COVID-19 vaccine demand, while maintaining significant R&D investment to advance its oncology pipeline.

BioNTech posted €1.52 billion in revenue for Q3 2025, driven by partnership-related income, but reported a net loss of €28.7 million as R&D and other operating costs rose.

Revenues doubled year-over-year driven by COVID-19 vaccine collaboration, but BioNTech still recorded a substantial net loss while progressing its oncology strategy and acquiring CureVac.

BioNTech's Q1 2025 results showed a net loss of €415.8 million on revenues of €182.8 million, primarily driven by reduced COVID-19 vaccine demand. The company continued advancing its oncology pipeline and maintained a strong cash position.

BioNTech's Q4 2024 revenue declined to €1.19 billion from €1.48 billion in Q4 2023, primarily due to reduced COVID-19 vaccine demand. Net profit also decreased to €259.5 million from €457.9 million in the prior year quarter. The company continues to advance its oncology pipeline, with multiple Phase 3 trials initiated. Cash and cash equivalents, including investments, remained strong at €17.4 billion.